Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol 2013; 19(2): 265-273 [PMID: 23345950 DOI: 10.3748/wjg.v19.i2.265]
Corresponding Author of This Article
Jae Hee Cheon, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. geniushee@yuhs.ac
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2013; 19(2): 265-273 Published online Jan 14, 2013. doi: 10.3748/wjg.v19.i2.265
Table 1 Baseline characteristics of patients with active ulcerative colitis receiving intravenous corticosteroids after oral corticosteroid therapy failure
Total patients (n = 67)
Gender (male/female)
39/28 (58.2/41.8)
Age (yr)
35 (13-78)
Age at diagnosis (yr)
31 (11-78)
Disease duration (mo)
24 (0-132)
Disease extent
Proctitis
5 (7.5)
Left-sided colitis
21 (31.3)
Extensive colitis
41 (61.2)
First attack of UC
32 (47.8)
Number of previous flares
2 (1-4)
Initial disease activity
Full Mayo score
9 (5-10)
Partial Mayo score
6 (3-7)
Initial prednisolone dose (mg)
≥ 30 and < 40
35 (52.2)
≥ 40
32 (47.8)
Duration of oral corticosteroid use (d)
13 (3-50)
Maintenance before flare up
None/salicylates/azathioprine
6/47/14
Concomitant medications
Salicylates
53
Azathioprine
14
CRP (mg/dL)
10.9 (0.1-153.0)
ESR (mm/h)
40.0 (3.0-120.0)
Hemoglobin (mg/dL)
11.7 (6.4-16.5)
Albumin (mg/dL)
3.6 (2.3-5.0)
Table 2 Comparison of clinical factors in immediate outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Table 3 Comparison of clinical factors in one month outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Table 4 Comparison of clinical factors in three month outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Table 5 Comparison of clinical factors in one year outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Citation: Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol 2013; 19(2): 265-273